Chemomab Therapeutics Ltd DRC (CMMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) has a cash flow conversion efficiency ratio of -0.230x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.90 Million) by net assets ($17.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chemomab Therapeutics Ltd DRC - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Chemomab Therapeutics Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Chemomab Therapeutics Ltd DRC total liabilities for a breakdown of total debt and financial obligations.
Chemomab Therapeutics Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chemomab Therapeutics Ltd DRC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
0.065x |
|
Jwwinvest
WAR:JWW
|
0.191x |
|
Revenue Group Bhd
KLSE:0200
|
0.178x |
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
-0.335x |
|
RUGBY RESOURCES LTD
F:64O
|
N/A |
|
Wong Engineering Corporation Bhd
KLSE:7050
|
-0.012x |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
N/A |
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
-0.116x |
Annual Cash Flow Conversion Efficiency for Chemomab Therapeutics Ltd DRC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Chemomab Therapeutics Ltd DRC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see CMMB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.54 Million | $-15.46 Million | -1.142x | +17.58% |
| 2023-12-31 | $17.00 Million | $-23.55 Million | -1.386x | -147.35% |
| 2022-12-31 | $36.22 Million | $-20.29 Million | -0.560x | -178.05% |
| 2021-12-31 | $61.47 Million | $-12.38 Million | -0.201x | +83.00% |
| 2020-12-31 | $10.80 Million | $-12.80 Million | -1.185x | -7.01% |
| 2019-12-31 | $14.91 Million | $-16.51 Million | -1.107x | +23.41% |
| 2018-12-31 | $9.80 Million | $-14.18 Million | -1.446x | -110.26% |
| 2017-12-31 | $-609.00K | $-8.58 Million | 14.090x | +1342.12% |
| 2016-12-31 | $3.29 Million | $-3.74 Million | -1.134x | +67.03% |
| 2015-12-31 | $2.14 Million | $-7.38 Million | -3.441x | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing ch… Read more